X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
Details:
The COMPASS trial was designed to investigate the efficacy and safety of dosing ferric citrate twice-daily as compared to the current U.S. FDA approved dosing of ferric citrate three times daily in adult patients with chronic kidney disease (CKD) not on dialysis.
Lead Product(s): Ferric Citrate
Therapeutic Area: Hematology Product Name: Auryxia
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
The NDA is based on JT and Torii's Phase 3 clinical study and other clinical studies in adult patients with IDA in Japan.
Lead Product(s): Ferric Citrate
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
